Investment Rating - The report maintains a "Buy" rating for Kangchen Pharmaceutical (603590) [1] Core Views - Kangchen Pharmaceutical has significant market potential in the hemostatic enzyme sector, with smooth clinical progress in its pipeline [1] - The company achieved a revenue of 692 million yuan in the first three quarters of 2025, representing a year-on-year growth of 7.10%, while the net profit attributable to shareholders increased by 13.19% to 128 million yuan [3][4] - The marketing transformation initiated in 2024 has led to a reduction in sales expense ratio and enhanced market potential for its core product, Su Ling [5] - The company is actively advancing its innovative drug pipeline, with promising results from clinical trials for KC1086 and KC1036 [6][7] Financial Performance - For 2025, the company is projected to achieve revenues of 905 million yuan, with a year-on-year growth rate of 9.60% [9] - The net profit attributable to shareholders is expected to reach 140 million yuan in 2025, reflecting a substantial growth of 231.03% [9] - The earnings per share (EPS) for 2025 is estimated at 0.88 yuan, with a price-to-earnings (PE) ratio of 56 times [9][7] Pipeline Development - The clinical trial for KC1086, a small molecule inhibitor, has shown over 90% tumor suppression in models for ER+/HER2- breast cancer, with the first patient enrolled in August 2025 [6] - KC1036 is undergoing multiple clinical trials for advanced esophageal squamous cell carcinoma, with promising results expected [6][7] - The company is also developing KC1101 and KC5827, with clinical trials anticipated to start in 2026 [7]